| Overview | M-hydroxylamine mainly acts on α receptor, but weakly on β1 receptor; part of the effect is by promoting the release of norepinephrine from sympathetic nerve endings. It is suitable for the treatment of early Shock, and the prevention and treatment of acute hypotension during spinal anesthesia. It can also be used for adjuvant symptomatic treatment of hypotension due to bleeding, drug allergy, surgical complications and brain trauma or brain tumor with Shock, and also for the treatment of hypotension due to cardiogenic Shock or sepsis. |
| Use | is an adrenergic mimetic drug, used for acute hypotension, and is one of the commonly used drugs for rescuing patients. |
| production method | M-hydroxybenzaldehyde (see 21680) is prepared by enzymatic addition, condensation and catalytic hydrogenation to obtain m-hydroxylamine. The M-hydroxylamine ethanol solution was added with tartaric acid to form a salt, and the precipitated crude product was recrystallized with anhydrous and no alcohol to obtain m-hydroxylamine bitartrate. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
